Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
Authors
Keywords
-
Journal
Frontiers in Cardiovascular Medicine
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-08-31
DOI
10.3389/fcvm.2022.990182
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inflammation in obesity, diabetes, and related disorders
- (2022) Theresa V. Rohm et al. IMMUNITY
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
- (2022) Dominik Dahl et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus
- (2022) Zheng Zhou et al. Frontiers in Cellular and Infection Microbiology
- Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
- (2022) Amelia D. Dahlén et al. Frontiers in Pharmacology
- Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus
- (2022) Leilei Du et al. BIOMEDICINE & PHARMACOTHERAPY
- Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
- (2022) Thomas Karagiannis et al. DIABETOLOGIA
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
- (2022) Naveed Sattar et al. NATURE MEDICINE
- Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
- (2022) Tim Heise et al. Lancet Diabetes & Endocrinology
- Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus
- (2022) Jinyoung Kim et al. Diabetes & Metabolism Journal
- TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial
- (2022) Deepa Joshi et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- The Correlation of Prediabetes and Type 2 Diabetes With Adiposity in Adults
- (2022) Juan Sun et al. Frontiers in Nutrition
- Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus
- (2021) Long Cheng et al. Adipocyte
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Glucagon‐like peptide‐1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?
- (2021) Tito Borner et al. BRITISH JOURNAL OF PHARMACOLOGY
- Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
- (2021) Mathies M. Jepsen et al. EXPERT OPINION ON EMERGING DRUGS
- Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
- (2021) Mohamad Sirri Tarazi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Dietary strategies for remission of type 2 diabetes: A narrative review
- (2021) Adrian Brown et al. JOURNAL OF HUMAN NUTRITION AND DIETETICS
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-diabetic drugs and weight loss in patients with type 2 diabetes
- (2021) Elisa Lazzaroni et al. PHARMACOLOGICAL RESEARCH
- A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
- (2021) Kenichi Furihata et al. DIABETES OBESITY & METABOLISM
- Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
- (2021) Valentina Pirro et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials
- (2021) Akshaya Srikanth Bhagavathula et al. Pharmaceuticals
- Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers
- (2021) Clinical Diabetes
- The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
- (2020) Jonathan M. Wilson et al. DIABETES OBESITY & METABOLISM
- Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
- (2020) Melissa K Thomas et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
- (2020) Thinzar Min et al. Diabetes Therapy
- Separate and Combined Gluco-Metabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in Healthy Individuals
- (2019) Lærke S. Gasbjerg et al. DIABETES
- Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
- (2019) Alice E. Adriaenssens et al. Cell Metabolism
- 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Insulin therapy, weight gain and prognosis
- (2018) Israel Hodish DIABETES OBESITY & METABOLISM
- Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Dalong Zhu et al. Lancet Diabetes & Endocrinology
- Efficacy and Safety of Once-weekly Dulaglutide Versus Insulin Glargine in Mainly Asian Patients with Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea: a 52-week Open-label, Randomized Phase 3 Trial
- (2018) Weiqing Wang et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite?
- (2018) John I. Malone et al. PEDIATRIC DIABETES
- Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
- (2017) Yan Zheng et al. Nature Reviews Endocrinology
- rDNA insulin glargine U300 – a critical appraisal
- (2016) Fei Wang et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
- (2015) Ulrike Hostalek et al. DRUGS
- Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis
- (2012) Feng Sun et al. Experimental Diabetes Research
- Basal Insulin: Physiology, Pharmacology, and Clinical Implications
- (2011) Kevin D. Niswender POSTGRADUATE MEDICINE
- Insulin glargine and its role in glycaemic management of Type 2 diabetes
- (2008) MA Elrishi et al. Expert Opinion on Drug Metabolism & Toxicology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started